Vaccine development – strategic approach
This white paper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
This white paper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.
Cancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Cancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.
AXA IM Alts has raised €1.9bn of equity to accelerate investments into the Life Sciences sector.
Synaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Mainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals.
Coventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
As part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Oslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
This white paper explores the drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.